Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Montelukast, a selective leukotriene receptor antagonist (LTRA), is a widely prescribed pharmaceutical agent primarily utilized in the management of asthma and allergic rhinitis. Its chemical identity is defined by the molecular formula C35H36ClNO3S, and it is uniquely identified by the CAS registry number 159789-28-5. Structurally, Montelukast features a complex arrangement including a biphenyl moiety and a thioether linkage, which enables high-affinity binding to the cysteinyl leukotriene type 1 (CysLT1) receptor. By blocking this receptor, the drug effectively inhibits the biological activity of cysteinyl leukotrienes, potent inflammatory mediators that cause bronchoconstriction, mucus secretion, and airway edema.
Clinically, Montelukast serves as a crucial maintenance therapy for chronic asthma across various age groups, from infants to adults. Unlike short-acting bronchodilators used for acute attacks, Montelukast provides long-term control by reducing inflammation and preventing symptoms triggered by exercise, allergens, or cold air. It is particularly valuable for patients with aspirin-exacerbated respiratory disease, where traditional NSAIDs induce severe asthmatic reactions. Furthermore, the medication is approved for the symptomatic relief of seasonal and perennial allergic rhinitis, helping to alleviate nasal congestion, sneezing, and runny nose associated with pollen or dust exposure. The drug is typically administered orally once daily in tablet, chewable tablet, or granule form, offering convenient dosing schedules that enhance patient compliance. While generally well-tolerated, clinicians monitor for rare neuropsychiatric events, including mood changes or sleep disturbances, ensuring a balanced risk-benefit profile. As a cornerstone in modern respiratory care, Montelukast significantly improves quality of life by stabilizing airway function and minimizing reliance on corticosteroids in mild-to-moderate cases. Its mechanism of action targets specific pathways distinct from beta-agonists, making it an essential component of comprehensive asthma management strategies worldwide.